期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (4)
Purpose Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial fibrillation (AF), with guidelines preferring non-vitamin K ......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (4)
Purpose Noonan syndrome with multiple lentigines (NSML) is an autosomal dominant disorder presenting with hypertrophic cardiomyopathy (HCM). Up to 85%......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (6)
Purpose Macrophage apoptosis coupled with a defective phagocytic clearance of the apoptotic cells promotes plaque necrosis in advanced atherosclerosis......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (6)
While there are physiologic differences in lipid metabolism in men and women, pharmacologic therapy is very effective in both with similar management ......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (1)
The widespread availability of highly effective antiretroviral therapies has reduced mortality from opportunistic infections in persons living with HI......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (4)
Purpose Wire-based coronary physiology pullback performed before percutaneous coronary intervention (PCI) discriminates coronary artery disease (CAD) ......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (3)
Background The optimal dosing strategy of four-factor prothrombin complex concentrate (4F-PCC) for vitamin K antagonists (VKAs) reversal is unknown. M......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (4)
Purpose Although the cardioprotective benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors are now widely appreciated, the mechanisms underly......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (4)
Purpose Diabetes mellitus (DM) is a major risk factor for the development of heart failure (HF). Sodium-glucose co-transporter 2 (SGLT2) inhibitors ha......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (5)
Purpose Both warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) have pleiotropic effects including anti-inflammatory and anti-fibrotic ......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (4)
Purpose Available animal models of acute heart failure (AHF) and their limitations are discussed herein. A novel and preclinically relevant porcine mo......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (1)
Background Acute coronary syndrome (ACS) is a serious and life-threatening condition. Anticoagulation during the acute phase of ACS is effective in re......
期刊： CARDIOVASCULAR DRUGS AND THERAPY, 2022; 36 (2)
Purpose Between 2012 and 2017, the FDA approved 29 therapies for a cardiovascular disease (CVD) indication. Due to the limited literature on patient s......
